NCT04492514View on ClinicalTrials.gov

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

November 16, 2020

Study Completion Date

November 16, 2020

Conditions
COVID 19SARS-CoV 2Pneumonia
Interventions
DRUG

Mavrilimumab

Treatment infusion

DRUG

Placebo

Placebo infusion

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

Sponsors
All Listed Sponsors
collaborator

Kiniksa Pharmaceuticals, Ltd.

INDUSTRY

lead

Kristin Hudock

OTHER

NCT04492514 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Biotech Hunter | Biotech Hunter